At the same time, there is clear room for improvement, as the patients responding to immunological treatments are still the minority,26,50 with some exceptions (e.g., CAR T therapies in some hematological malignancies or anti-programmed cell death-1 [PD1] in selected indications). This evidence concerns the gene PDCD1 and hematologic disorder.